Abstract 2329P
Background
Although it is an important biomarker in oncology, Ki-67 immunohistochemistry analysis has yet to be standardized. Working groups have provided guidelines for Ki-67 scoring in different cancer types to limit pathologist’s variability. Digital analysis solutions to assist scoring with image analysis or AI have recently emerged in the evaluation of Ki-67 as rapid and robust solutions. In this context, we compared the results of Ki-67 scoring performed with Aiforia® (AI platform) and Halo® (image analysis supervised software) against two independent pathologists on solid tumors.
Methods
We stained 192 tumors of various origins including breast and prostate with Ki-67 (clone 30-9). Pathologists were trained following the International Ki-67 Working Group recommendations and scored tissues accordingly. Based on deep learning, Aiforia was able to automatically score Ki-67 positive tumor cells within minutes. The random forest classifier from Halo software was used to separate the image into tumor, non-tumor and background. After cell segmentation, Ki-67 positivity was assessed by thresholding.
Results
Our study shows a very high consistency of results obtained for Ki-67 scoring between the image analysis softwares, Aiforia and Halo (r2=0.94), on all solid tumors. The correlation obtained between the two pathologists was weaker (r2=0.8), despite the training and guidelines, but remains within an acceptable range. Of the 18 types of primary tumors analyzed, only 2 (thyroid and stomach) showed correlations of less than 0.75 between the image analysis softwares with inter-pathologists' correlation still high (0.73 and 0.86). Depending on the organ, there were significant variations between pathologists, whereas the scores obtained with the image analysis softwares remain very close. For example, with prostate (n=8), a 0.81 correlation for Ki-67 scores between Aiforia and Halo was found while the inter-pathologists' correlation was 0.68.
Conclusions
This work shows that AI based image analysis tools such as Aiforia and image analysis supervised software provide valuable assistance in IHC based clinical analysis, drastically reducing inter-pathologist variability or as an arbitration tool in Ki-67 scoring of solid tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2336P - MiR-155 overexpression regulates epithelial-mesenchymal transition through repressing Quaking in lung cancer cells
Presenter: Jung-Jyh Hung
Session: Poster session 16
2337P - Feasibility of mutation detection in cytological samples from metastasis in patients with metastatic prostate cancer
Presenter: Marina Mencinger
Session: Poster session 16
2338P - The phenotype of tumor-associated macrophages in human high-grade serous ovarian carcinoma
Presenter: Irina Larionova
Session: Poster session 16
2339P - Clinical and genomic correlates of plasma circulating tumor DNA (ctDNA) tumor fraction (TF) in patients with advanced NSCLC
Presenter: Filippo Dall'Olio
Session: Poster session 16
2340P - T-cell immunoglobulin and mucin-domain containing molecule-3 (Tim3) in breast cancer and the impact on penetration of blood brain barrier by cancer cells
Presenter: Xiaoshan Cao
Session: Poster session 16
2341P - Novel therapeutic opportunities in metaplastic breast cancer
Presenter: Fresia Pareja
Session: Poster session 16
2342P - Single tumor cells are a novel prognostic criterion in breast cancer patients
Presenter: Liubov Tashireva
Session: Poster session 16
2343P - Evolution of circulating tumour DNA analysis in France over 5 years
Presenter: Guillaume Herbreteau
Session: Poster session 16
2345P - The possibility of programmed death-ligand 1-related immune modulation in neoadjuvant thermoradiotherapy for rectal cancer
Presenter: seihwan you
Session: Poster session 16
2346P - Spatial and quantified molecular characterization of high endothelial venule predictive of immunotherapy response
Presenter: Kunheng Du
Session: Poster session 16